NeuroMetrix (NASDAQ:NURO) Stock Price Passes Above Two Hundred Day Moving Average – Should You Sell?

NeuroMetrix, Inc. (NASDAQ:NURO) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.85 and traded as high as $4.17. NeuroMetrix shares last traded at $4.15, with a volume of 12,828 shares trading hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of NeuroMetrix in a research note on Friday. They issued a “sell” rating for the company.

NeuroMetrix Trading Down 2.1 %

The firm has a 50 day moving average of $3.75 and a two-hundred day moving average of $3.85. The stock has a market capitalization of $8.17 million, a PE ratio of -0.64 and a beta of 2.29.

NeuroMetrix (NASDAQ:NURO) last released its quarterly earnings data on Tuesday, August 6th. The medical device company reported ($0.74) EPS for the quarter. The business had revenue of $0.77 million during the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.